Table 3.
Putative genetic associations with antipsychotic-induced TD and EPS studied from 2010 to 2015, and their related listings by expert PGx panels
| Gene | Polymorphism | Putative association | Listings by expert panels | References |
|---|---|---|---|---|
| CYP2D6 | CYP2D6*1, *2, *3, *4, *5, *6, *10, *41 | PM and IM status associated with a greater risk of TD or EPS | PharmGKB: evidence level 3a | [124, 125, 126, 127, 128, 129, 130, 131] |
| DPP6 | rs6977820 (T > C) | T allele associated with a greater risk of TD | PharmGKB: evidence level 2B | [149] |
| DRD2 | rs1800497 (Taq1A) | G allele associated with a greater risk of TD | PharmGKB: evidence level 2Bb CPIC: evidence level Dc | [136, 137, 138, 139] |
| SLC18A2 | rs2015586 (G/C) | C allele associated with a greater risk of TD | unlisted | [129, 140] |
| HSPG2 | rs2445142 (G > C); rs878949 (T > C)d | G and T allele associated with a greater risk of TD | PharmGKB: evidence level 3a | [145, 146, 147] |
References include both positive and negative findings. See references [19, 20] for further information on the PharmGKB and CPIC, as well as the criteria used to assign evidence levels.
a
Low evidence for this association.
b
Moderate evidence for this association.
c
Considered of interest.
d
Perfect proxy marker for rs2445142 (r2 = 1).